Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE

Herein we investigated how rituximab-induced B cell depletion affected leukocyte subpopulations and antibody titers in SLE patients. We focused our analysis on time points related to absence and return of B cells after depletion. A correlation was found between the baseline frequency and time to rep...

Description complète

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 122(2007), 1 vom: 01. Jan., Seite 62-74
Auteur principal: Vallerskog, Therese (Auteur)
Autres auteurs: Gunnarsson, Iva, Widhe, Mona, Risselada, Anke, Klareskog, Lars, van Vollenhoven, Ronald, Malmström, Vivianne, Trollmo, Christina
Format: Article
Langue:English
Publié: 2007
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Clinical Trial Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Autoantibodies Immunoglobulins Immunologic Factors Rituximab 4F4X42SYQ6